Insulin Pump

Since early in the 1970s, there was evidence that supported the theory that firm control of diabetes prevented or slowed the complications of Type I diabetes. This was helped by the development of reliable methods of assessing glycemic control (Hb A1c) and the development of accurate methods of assessing diabetes. The "Diabetic Control and Complication Trial" (DCCT) proved that tight control of diabetes prevented or slowed the chronic complications of this condition. In the study arm in which patients received intensive treatment, either by multiple daily injections (MDI) or by continuous subcutaneous insulin infusion (CSII) there was a 70% reduction in the progression of diabetic retinopathy; 50% reduction in diabetic nephropathy and 64% reduction in diabetic neuropathy. Based on these results the "American Diabetes Association" revised its standard of care and recommended target glycemic control at normal levels in most patients with Type I Diabetes. The continuous infusion system ("Continuous Subcutaneous Insulin Infusion- CSSI") is a system of subcutaneous insulin infusion using a programmable pump that provides a continuous and stable flow. This flow can be programmed to manage the amount depending on the metabolic needs of the patient who is using it. It can be programmed to supply greater amounts of insulin to cover meals intake. This provides the patient more flexibility to suit their lifestyles. Some studies show that users of this system maintain levels of glycosylated hemoglobin (Hb A1c) within normal ranges, hypoglycemic episodes are reduced, and fewer emergency room visits and hospitalizations. This system has the following advantages: Improves metabolic control and glucose levels are achieved near normal • Reduce the risk of micro and macrovascular complications: 1. retinopathies reduce the risk of developing it by 76%, if there is reduced progression by 54% 2. Kidney Diseases-proteinuria is reduced by 54% 3. Neuropathies- risk is reduced by 60% • CSSI uses only rapid-acting insulin that provides a reproducible and predictable absorption • Use a single area for injection thus avoiding variations in absorption of body parts • Insulin does not accumulate in a subcutaneous depot, reducing the risk of mobilizing the deposit at a given moment and produce hypoglycemia. • better glycemic control while avoiding hypoglycemia night at dawn is obtained Patient selection is very important if you want to get the maximum effect of the insulin pump. The following characteristics should serve as a warning about who is not a good candidate for using the insulin pump: Child, adolescent or adult with poor family support. • Unwilling or unable to be monitored blood glucose three to four times a day. • Unwilling or unable to calculate how many meals. • Difficulty to calculate or adjust insulin doses, or to face difficulties with the pump. • Difficulty to follow instructions or comply with doctor visits. • Ashamed to be known diabetic and dependent on a mechanical device. • unstable psychiatric profile. <a id="